Subtopic Deep Dive
VEXAS Syndrome Pathogenesis
Research Guide
What is VEXAS Syndrome Pathogenesis?
VEXAS Syndrome Pathogenesis investigates somatic UBA1 mutations driving adult-onset autoinflammation through ubiquitin dysregulation and neutrophil hyperactivity.
Somatic mutations in UBA1, particularly at methionine 41, cause VEXAS syndrome, characterized by vacuoles in myeloid cells and systemic inflammation (Ferrada et al., 2022, 163 citations). Research employs genomic sequencing and functional assays to link these mutations to chondritis and hematologic abnormalities. Over 10 key papers since 2021 document mutation spectra and clinical overlaps with relapsing polychondritis.
Why It Matters
VEXAS pathogenesis reveals mechanisms of late-onset autoinflammatory diseases, enabling distinction from idiopathic relapsing polychondritis for precise diagnosis (Khitri et al., 2022, 82 citations). It guides therapies targeting ubiquitination defects, as cytoplasmic UBA1 translation contributes to neutrophil dysregulation (Ferrada et al., 2022). Studies on clonal hematopoiesis in VEXAS inform MDS management in inflammatory contexts (Gutierrez-Rodrigues et al., 2023, 98 citations).
Key Research Challenges
Detecting Low-VAF Mutations
Somatic UBA1 mutations often have low variant allele frequencies, complicating detection in heterogeneous tissues (Templé et al., 2021, 70 citations). Standard sequencing misses atypical splice-site variants. Advanced transcriptome methods are needed for comprehensive screening (Sakuma et al., 2023, 57 citations).
Linking Mutations to Inflammation
Translating UBA1 defects to autoinflammatory phenotypes requires functional assays beyond sequencing (Ferrada et al., 2022, 163 citations). Ubiquitination pathway disruptions lead to neutrophil hyperactivity, but causal chains remain unclear. Models for chondritis and vasculitis overlap need validation (Watanabe et al., 2022, 56 citations).
Differentiating VEXAS from Mimics
VEXAS overlaps with relapsing polychondritis and vasculitis, delaying diagnosis without UBA1 testing (Muratore et al., 2021, 89 citations). Idiopathic vs. VEXAS polychondritis differs in hematologic features and outcomes (Khitri et al., 2022, 82 citations). Standardized criteria are lacking for sporadic cases (Al-Hakim and Savic, 2022, 81 citations).
Essential Papers
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis
Marcela A. Ferrada, Sinisa Savic, Daniela Ospina Cardona et al. · 2022 · Blood · 163 citations
Abstract Somatic mutations in UBA1 cause vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory somatic (VEXAS) syndrome, an adult-onset inflammatory disease with an overlap of hemato...
Disorders of ubiquitylation: unchained inflammation
David B. Beck, Achim Werner, Daniel L. Kastner et al. · 2022 · Nature Reviews Rheumatology · 116 citations
Spectrum of clonal hematopoiesis in VEXAS syndrome
Fernanda Gutierrez‐Rodrigues, Yael Kusne, Jenna Fernandez et al. · 2023 · Blood · 98 citations
VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic ...
<scp>VEXAS</scp> Syndrome: A Case Series From a <scp>Single‐Center</scp> Cohort of Italian Patients With Vasculitis
Francesco Muratore, Chiara Marvisi, Paola Castrignanò et al. · 2021 · Arthritis & Rheumatology · 89 citations
Objective To identify patients with VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome) from a single‐center cohort of Italian patients with vasculitis, using a clini...
Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients
Mohamed-Yacine Khitri, Alexis F. Guédon, Sophie Georgin‐Lavialle et al. · 2022 · RMD Open · 82 citations
Objective A new adult-onset autoinflammatory syndrome has been described, named VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic). We aimed to compare the clinical characteristics, t...
An update on VEXAS syndrome
Adam Al‐Hakim, Sinisa Savic · 2022 · Expert Review of Clinical Immunology · 81 citations
New rare variants in <i>UBA1</i> and VEXAS-like <i>UBA1</i> negative cases are reported. Consensus diagnostic criteria might be required to define VEXAS and its related disorders. Investigation of ...
Atypical splice-site mutations causing VEXAS syndrome
Marie Templé, Eugénie Duroyon, Carolyne Croizier et al. · 2021 · Lara D. Veeken · 70 citations
Dear Editor, Recently described in male patients [1], somatic UBA1 (Ubiquitin Like Modifier Activating Enzyme 1) mutations affecting methionine 41 (M41) are now considered as key features of a new ...
Reading Guide
Foundational Papers
No pre-2015 foundational papers available; start with Beck et al. (2022, Nature Reviews Rheumatology, 116 citations) for ubiquitylation overview and Ferrada et al. (2022, Blood, 163 citations) for core pathogenesis mechanisms.
Recent Advances
Gutierrez-Rodrigues et al. (2023, Blood, 98 citations) on clonal hematopoiesis spectrum; Sakuma et al. (2023, Leukemia, 57 citations) on novel variants via transcriptome sequencing.
Core Methods
Whole-genome transcriptome sequencing for variants (Sakuma et al., 2023); functional assays of cytoplasmic UBA1 (Ferrada et al., 2022); clinical-genomic correlation in cohorts (Muratore et al., 2021).
How PapersFlow Helps You Research VEXAS Syndrome Pathogenesis
Discover & Search
Research Agent uses searchPapers and exaSearch to query 'UBA1 somatic mutations VEXAS pathogenesis' yielding Ferrada et al. (2022, Blood, 163 citations) as top hit, then citationGraph maps forward citations to Gutierrez-Rodrigues et al. (2023) on clonal hematopoiesis, and findSimilarPapers uncovers atypical variants in Templé et al. (2021).
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation spectra from Ferrada et al. (2022), verifies claims with CoVe against Khitri et al. (2022), and runs PythonAnalysis on citation data for statistical trends in VAF distributions across 10 papers, with GRADE grading assigning high evidence to functional assays.
Synthesize & Write
Synthesis Agent detects gaps in thrombosis mechanisms post-Watanabe et al. (2022), flags contradictions between idiopathic and VEXAS polychondritis from Khitri et al. (2022); Writing Agent uses latexEditText for pathogenesis diagrams, latexSyncCitations for 20-paper bibliography, and latexCompile for review export.
Use Cases
"Analyze VAF distributions in UBA1 mutations from VEXAS papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of VAF data from Ferrada et al. 2022 and Gutierrez-Rodrigues et al. 2023) → matplotlib plot of mutation frequencies.
"Draft LaTeX review on VEXAS vs relapsing polychondritis"
Synthesis Agent → gap detection → Writing Agent → latexEditText (pathogenesis section) → latexSyncCitations (Khitri et al. 2022 et al.) → latexCompile → PDF with ubiquitin pathway figure.
"Find code for UBA1 variant calling in VEXAS studies"
Research Agent → paperExtractUrls (Sakuma et al. 2023) → paperFindGithubRepo → githubRepoInspect → code snippets for transcriptome-based mutation detection.
Automated Workflows
Deep Research workflow scans 50+ VEXAS papers via searchPapers → citationGraph → structured report on pathogenesis evolution from Ferrada et al. (2022). DeepScan applies 7-step CoVe to verify mutation-phenotype links in Muratore et al. (2021) with GRADE checkpoints. Theorizer generates hypotheses on ubiquitination defects from Beck et al. (2022) inputs.
Frequently Asked Questions
What defines VEXAS Syndrome Pathogenesis?
Somatic UBA1 mutations, especially M41 variants, disrupt ubiquitination leading to autoinflammation and myeloid vacuoles (Ferrada et al., 2022).
What methods study VEXAS pathogenesis?
Genomic sequencing detects mutations, functional assays assess ubiquitin activity, and transcriptome analysis identifies atypical variants (Sakuma et al., 2023; Templé et al., 2021).
What are key papers on VEXAS pathogenesis?
Ferrada et al. (2022, Blood, 163 citations) on cytoplasmic UBA1 translation; Gutierrez-Rodrigues et al. (2023, Blood, 98 citations) on clonal hematopoiesis; Beck et al. (2022, Nature Reviews Rheumatology, 116 citations) on ubiquitylation disorders.
What open problems exist in VEXAS research?
Therapeutic targeting of ubiquitination defects, differentiation from idiopathic polychondritis, and mechanisms of thrombosis remain unresolved (Al-Hakim and Savic, 2022; Oo et al., 2021).
Research Otitis Media and Relapsing Polychondritis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching VEXAS Syndrome Pathogenesis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers